Pharmafile Logo
Pharmafocus logo
Advanced Search

immuno-oncology

Showing 15 posts of 36 posts found.

Astellas and Kelonia Therapeutics enter agreement for development of immuno-oncology therapeutics

February 16, 2024
Research and Development Astellas Pharma, Kelonia Therapeutics, Oncology, collaboration, immuno-oncology

Astellas Pharma and Kelonia Therapeutics have announced that Xyphos Biosciences (a wholly owned subsidiary of Astellas) and Kelonia have entered …

News
shutterstock_360472550

MSD teams up with Harvard University to discover novel immune system pathways to fight cancer

August 13, 2019
Manufacturing and Production, Research and Development Cancer, Harvard, MSD, Merck, immuno-oncology, oncology, pharma

A new partnership between MSD and Harvard University hopes to combine the expertise of both parties to carve a path …

News
sobi_offices

Sobi acquire Novimmune in deal worth more than £400 million

June 13, 2019
Business Services, Research and Development R&D, emapalumab, immuno-oncology, immunology, pharma

Swedish rare disease specialist Sobi has agreed to buy Swiss firm Novimmune ion a deal worth more than £400 million. …

News
amgen_flag

Amgen agrees to buy Nuevolution for $167 million

May 22, 2019
Research and Development Amgen, Cancer, Nuevolution, biotech, drug discovery, immuno-oncology, immunology, pharma

California biotech Amgen has agreed to buy Danish biopharmaceutical company Nuevolution AB for 1.61 billion Swedish crowns ($166.8 million). The …

News
dmitry_nuyten

Pfizer immune-oncology leader joins Aduro Biotech as new CMO

April 23, 2019
Manufacturing and Production Aduro Biotech, Cancer, Pfizer, immuno-oncology, immunotherapy, oncology

Pfizer’s vice president and head of immune-oncology clinical development has joined Aduro Biotech as the company’s new Chief Medical Officer, …

News
celgene_1_02

Celgene signs deals with two Massachusetts-based biotechs

January 21, 2019
Sales and Marketing Celgene, Kyn, Obsidian, cell therapy, immuno oncology, immuno-oncology

New Jersey-based biotechnology firm Celgene has signed deals with two Massachusetts-based biotechs: immuno-oncology specialist Kyn therapeutics and cell therapy firm …

News
gilead-sciences

Gilead inks $1.8 bn deal with immuno-oncology biotech Agenus

December 21, 2018
Medical Communications Agenus, Gilead, Lexington, Massachusetts, USA, immuno-oncology, oncology

California-based firm Gilead Sciences and Massachusetts-based immuno-oncology biotech Agenus have announced that they have entered into a partnership focused on …

News

Roche acquires immuno-oncology biotech Tusk in €655m deal

October 1, 2018
Sales and Marketing Droia, Roche, Tusk, immuno-oncology, immunology, oncology

Swiss multinational Roche has acquired the privately held immuno-oncology company Tusk Therapeutics in a deal that could be worth up …

News
msd

MSD says Phase III trials for Keytruda to treat advanced melanoma shows better survival

June 8, 2016
Research and Development ASCO, MSD, Merck & Co, PD-L1, advanced melanoma, drug trial, immuno-oncology, keytruda

Merck & Co (NYSE: MRK) said late-stage trials for its immunotherapy Keytruda (pembrolizumab) to treat advanced melanoma showed over half …

News

Trial data shows promise for Lilly/MSD combo regimen in lung cancer

June 6, 2016
Research and Development, Sales and Marketing MSD, Merck, collaboration, immuno-oncology, lilly, lung cancer, non-small cell, parternship

Eli Lilly (NYSE: LLY) has presented data at the American Society of Clinical Oncology (ASCO) annual congress showcasing its collaborations …

News
abbvie_0

Abbvie acquires immune-oncology target from argenx

April 21, 2016
Research and Development, Sales and Marketing AbbVie, Protein, argenx, garp, immuno-oncology, immunosuppresive

AbbVie (NYSE:ABBV) has announced the acquisition of a new preclinical-stage human antibody program evaluating the novel immune-oncology target GARP, a …

News
opdivo_1_1

Focus: Bristol-Myers Squibb’s wonder drug – Opdivo

April 20, 2016
Research and Development, Sales and Marketing BMS, growth, immuno-oncology, opdivo, sales

By Anjali ShuklaNew data for Bristol-Myers Squibb’s (NYSE: BMY) Opdivo to treat head and neck cancer showed superior survival compared with …

Feature
clinicaltrial1

Sosei‘s Heptares And Kymab to collaborate on developing new antibody therapeutics

April 18, 2016
Research and Development, Sales and Marketing Heptares Therapeutics, Kymab Ltd, Sosei Group, collaboration, drug development, immuno-oncology

Japan’s Sosei Group Corp (TSE: 4565) has signed a collaboration deal with Kymab Ltd to develop and market novel antibody …

News
clinical_trial-web

OncoMed initiates Phase Ib immuno-oncology combination clinical trial

March 18, 2016
Medical Communications, Research and Development Merck, OncoMed, clinical trial, demcizumab, immuno-oncology, immuno-oncology combination, pembrolizumab, phase ib

OncoMed (NASDAQ: OMED) has announced the beginning of its Phase Ib clinical trial to investigate if the combination of demcizumab …

News
shutterstock_159488225

Vaxon Biotech completes enrollment for mid-stage trial of lung cancer vaccine

March 16, 2016
Research and Development, Sales and Marketing NSCLC, immuno-oncology, vaxon biotech

Vaxon Biotech on Wednesday said it has completed the enrollments for mid-stage trials of its vaccine to treat non-small-cell lung …

News

Latest content

Eli Lilly acquires new manufacturing facility from Nexus Pharmaceuticals

April 24, 2024

GSK’s Jemperli accepted for FDA review for endometrial cancer treatment

April 24, 2024

Sanofi shares results for phase 3 LUNA 3 trial in immune thrombocytopenia

April 23, 2024

FDA approves ImmunityBio’s Anktiva bladder cancer treatment

April 23, 2024

EC approves Pfizer’s Emblaveo for multidrug-resistant infection treatment

April 22, 2024